U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C19H25N5O4.ClH.2H2O
Molecular Weight 459.924
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TERAZOSIN HYDROCHLORIDE

SMILES

O.O.Cl.COC1=CC2=NC(=NC(N)=C2C=C1OC)N3CCN(CC3)C(=O)C4CCCO4

InChI

InChIKey=NZMOFYDMGFQZLS-UHFFFAOYSA-N
InChI=1S/C19H25N5O4.ClH.2H2O/c1-26-15-10-12-13(11-16(15)27-2)21-19(22-17(12)20)24-7-5-23(6-8-24)18(25)14-4-3-9-28-14;;;/h10-11,14H,3-9H2,1-2H3,(H2,20,21,22);1H;2*1H2

HIDE SMILES / InChI

Molecular Formula ClH
Molecular Weight 36.461
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C19H25N5O4
Molecular Weight 387.4329
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula H2O
Molecular Weight 18.0153
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/10503165

Terazosin (marketed as Hytrin or Zayasel) is a selective alpha1-antagonist used for treatment of symptoms of benign prostatic hyperplasia (BPH). It also acts to lower blood pressure, so it is a drug of choice for men with hypertension and prostate enlargement. All three receptor subtypes appear to be involved in maintaining vascular tone. The α1A-receptor maintains basal vascular tone while the α1B-receptor mediates the vasocontrictory effects of exogenous α1-agonists. Activation of α1-receptors activates Gq-proteins, which results in intracellular stimulation of phospholipases C, A2, and D. This results in mobilization of Ca2+ from intracellular stores, activation of mitogen-activated kinase and PI3 kinase pathways and subsequent vasoconstriction.

CNS Activity

Curator's Comment: Known to be CNS penetrant in rats Human data not available

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
TERAZOSIN HYDROCHLORIDE

Approved Use

are used to treat high blood preassure (hypertension); are also used to treat benign prostatic hyperplasia (BPH) in men

Launch Date

2000
Primary
TERAZOSIN HYDROCHLORIDE

Approved Use

are used to treat high blood preassure (hypertension); are also used to treat benign prostatic hyperplasia (BPH) in men

Launch Date

2000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
48 ng/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERAZOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
37 ng/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERAZOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
408 ng × h/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERAZOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
418 ng × h/mL
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERAZOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.4 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERAZOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FASTED
9.5 h
2 mg single, oral
dose: 2 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TERAZOSIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
8%
TERAZOSIN plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
80 mg 1 times / day multiple, oral
Highest studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1169
unhealthy
n = 14
Health Status: unhealthy
Condition: Hypertension
Population Size: 14
Sources: Page: p.1169
Disc. AE: Dizziness...
AEs leading to
discontinuation/dose reduction:
Dizziness
Sources: Page: p.1169
80 mg 1 times / day multiple, oral
Highest studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.903
unhealthy
n = 37
Health Status: unhealthy
Condition: Hypertension
Population Size: 37
Sources: Page: p.903
Disc. AE: Syncope...
AEs leading to
discontinuation/dose reduction:
Syncope (2.7%)
Sources: Page: p.903
20 mg 1 times / day multiple, oral
MTD
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.9
unhealthy
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia|Hypertension
Sources: Page: p.9
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia|Hypertension
Sources: Page: p.6
Other AEs: Syncope, Postural hypotension...
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Disc. AE: Dizziness, Asthenia...
AEs leading to
discontinuation/dose reduction:
Dizziness (6.7%)
Asthenia (3.8%)
Somnolence (2%)
Chest pain (1.6%)
Headache (1.2%)
Dyspnea (1.2%)
Prostate carcinoma (1%)
Sources: Page: p.409
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Disc. AE: Fever, Headache...
AEs leading to
discontinuation/dose reduction:
Fever (0.5%)
Headache (1.1%)
Postural hypotension (0.5%)
Syncope (0.5%)
Nausea (0.5%)
Dizziness (2%)
Vertigo (0.5%)
Dyspnea (0.5%)
Blurred vision (0.6%)
Amblyopia (0.6%)
Urinary tract infection (0.5%)
Sources: Page: p.12
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Disc. AE: Asthenia, Headache...
AEs leading to
discontinuation/dose reduction:
Asthenia (1.6%)
Headache (1.3%)
Palpitations (1.4%)
Postural hypotension (0.5%)
Syncope (0.5%)
Tachycardia (0.6%)
Nausea (0.8%)
Peripheral edema (0.6%)
Dizziness (3.1%)
Paresthesia (0.8%)
Somnolence (0.6%)
Dyspnea (0.9%)
Nasal congestion (0.6%)
Blurred vision (0.6%)
Sources: Page: p.16
AEs

AEs

AESignificanceDosePopulation
Dizziness Disc. AE
80 mg 1 times / day multiple, oral
Highest studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.1169
unhealthy
n = 14
Health Status: unhealthy
Condition: Hypertension
Population Size: 14
Sources: Page: p.1169
Syncope 2.7%
Disc. AE
80 mg 1 times / day multiple, oral
Highest studied dose
Dose: 80 mg, 1 times / day
Route: oral
Route: multiple
Dose: 80 mg, 1 times / day
Sources: Page: p.903
unhealthy
n = 37
Health Status: unhealthy
Condition: Hypertension
Population Size: 37
Sources: Page: p.903
Postural hypotension
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia|Hypertension
Sources: Page: p.6
Priapism
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia|Hypertension
Sources: Page: p.6
Syncope
10 mg 1 times / day multiple, oral (max)
Recommended
Dose: 10 mg, 1 times / day
Route: oral
Route: multiple
Dose: 10 mg, 1 times / day
Sources: Page: p.6
unhealthy
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia|Hypertension
Sources: Page: p.6
Prostate carcinoma 1%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Dyspnea 1.2%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Headache 1.2%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Chest pain 1.6%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Somnolence 2%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Asthenia 3.8%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Dizziness 6.7%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.409
unhealthy
n = 494
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 494
Sources: Page: p.409
Dyspnea 0.5%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Fever 0.5%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Nausea 0.5%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Postural hypotension 0.5%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Syncope 0.5%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Urinary tract infection 0.5%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Vertigo 0.5%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Amblyopia 0.6%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Blurred vision 0.6%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Headache 1.1%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Dizziness 2%
Disc. AE
20 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 20 mg, 1 times / day
Route: oral
Route: multiple
Dose: 20 mg, 1 times / day
Sources: Page: p.12
unhealthy
n = 636
Health Status: unhealthy
Condition: Benign Prostatic Hyperplasia
Sex: M
Population Size: 636
Sources: Page: p.12
Postural hypotension 0.5%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Syncope 0.5%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Blurred vision 0.6%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Nasal congestion 0.6%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Peripheral edema 0.6%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Somnolence 0.6%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Tachycardia 0.6%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Nausea 0.8%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Paresthesia 0.8%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Dyspnea 0.9%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Headache 1.3%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Palpitations 1.4%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Asthenia 1.6%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Dizziness 3.1%
Disc. AE
40 mg 1 times / day multiple, oral (max)
Studied dose
Dose: 40 mg, 1 times / day
Route: oral
Route: multiple
Dose: 40 mg, 1 times / day
Sources: Page: p.16
unhealthy
n = 859
Health Status: unhealthy
Condition: Hypertension
Population Size: 859
Sources: Page: p.16
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG

OverviewOther

Other InhibitorOther SubstrateOther Inducer


Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
yes
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
1998
A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction.
1999
Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
1999 Jun
Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
2000 Aug 15
Effect of terazosin on the lipid profile in patients with symptomatic benign prostatic hyperplasia.
2001
Lower urinary tract symptoms suggestive of benign prostatic obstruction--Triumph: the role of general practice databases.
2001
5alpha-reductase inhibitors: what role should they play?
2001 Dec
[The efficacy and safety of terazosin and tamsulosin in patients with urinary disturbance accompanying prostatic hypertrophy].
2001 Jan
A quantitative analysis of antagonism and inverse agonism at wild-type and constitutively active hamster alpha1B-adrenoceptors.
2001 Jan
Targeted transurethral microwave thermotherapy versus alpha-blockade in benign prostatic hyperplasia: outcomes at 18 months.
2001 Jan
alpha-Blockade improves symptoms suggestive of bladder outlet obstruction but fails to relieve it.
2001 Jan
Combined effect of terazosin and finasteride on apoptosis, cell proliferation, and transforming growth factor-beta expression in benign prostatic hyperplasia.
2001 Jan 1
Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
2001 Jul 1
Loss of nocturnal dipping of blood pressure and heart rate in obesity-induced hypertension in rabbits.
2001 Jul 20
Comparison of prazosin, terazosin and tamsulosin: functional and binding studies in isolated prostatic and vascular human tissues.
2001 Jun 1
Pharmacological blockade of brain alpha1-adrenoceptors as measured by ex vivo [3H]prazosin binding is correlated with behavioral immobility.
2001 May 25
Role of supraspinal alpha1-adrenoceptors for voiding in conscious rats with and without bladder outlet obstruction.
2002 Apr
Long-term risk of re-treatment of patients using alpha-blockers for lower urinary tract symptoms.
2002 Apr
Hypertension in L-NAME-treated diabetic rats depends on an intact sympathetic nervous system.
2002 Apr
Chronic cardiovascular and renal actions of leptin: role of adrenergic activity.
2002 Feb
Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects.
2002 Feb
The use of alpha-adrenoceptor antagonists in lower urinary tract disease.
2002 Feb
Modeling of relationships between pharmacokinetics and blockade of agonist-induced elevation of intraurethral pressure and mean arterial pressure in conscious dogs treated with alpha(1)-adrenoceptor antagonists.
2002 Feb
Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action.
2002 Jan 15
The efficacy of terazosin for treating benign prostatic hyperplasia: a multicentre clinical trial.
2002 May
Alpha1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction.
2002 May-Jun
Mice expressing the alpha(1B)-adrenergic receptor induces a synucleinopathy with excessive tyrosine nitration but decreased phosphorylation.
2002 Nov
Prophylactic versus therapeutic alpha-blockers after permanent prostate brachytherapy.
2002 Oct
Terazosin for treating symptomatic benign prostatic obstruction: a systematic review of efficacy and adverse effects.
2002 Oct
[alpha 1-receptor blockade in therapy of benign prostatic hyperplasia syndrome. Correct dosing for optimal effectiveness].
2002 Sep
[Comparison of prazosin, terazosin and tramsulosin: functional and binding studies in isolated prostatic and vascular human tissues].
2002 Sep
[Comparative evaluation of the efficacy of using terazosin and tamsulosin in patients with benign prostatic hyperplasia].
2002 Sep-Oct
Impact of alpha1-blockers in men with spinal cord injury and upper tract stasis.
2002 Summer
Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
2003 Apr
Sympathetic modulation of acute cutaneous flare induced by intradermal injection of capsaicin in anesthetized rats.
2003 Feb
Nitric oxide opposes glucose-induced hypertension by suppressing sympathetic activity.
2003 Feb
Identification of apoptotic and antiangiogenic activities of terazosin in human prostate cancer and endothelial cells.
2003 Feb
[Hepatotoxicity induced by terazosin].
2003 Feb 1
[Results of treatment of irritative symptoms and urinary retention in patients 1 year after radical retropubic prostatectomy].
2003 Jan-Feb
Role of epinephrine stimulation of CNS alpha1-adrenoceptors in motor activity in mice.
2003 Jul
The ICH guidance in practice: stress decomposition studies on three piperazinyl quinazoline adrenergic receptor-blocking agents and comparison of their degradation behaviour.
2003 Mar 26
Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia.
2003 Nov
[Pharmacologic treatment of benign prostatic hyperplasia].
2003 Sep 14
Regulatory considerations of pharmaceutical solid polymorphism in Abbreviated New Drug Applications (ANDAs).
2004 Feb 23
Validated specific HPLC methods for determination of prazosin, terazosin and doxazosin in the presence of degradation products formed under ICH-recommended stress conditions.
2004 Jan 27
Patents

Sample Use Guides

In Vivo Use Guide
for Hypertension: Initial dose: 1 mg orally once a day at bedtime; Maintenance dose: 1-5 mg orally once a day. Maximum dose: 20 mg per day. Usual Adult Dose for Benign Prostatic Hyperplasia: Initial dose: 1 mg orally once a day at bedtime. Maintenance dose: Increased in a stepwise fashion to 2 mg, 5 mg, or 10 mg once a day to achieve desired improvement of symptoms.
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: TZ (terazosin) has a new protein target, Pgk1 (phosphoglycerate kinase 1), and reveal its corresponding biological effect. As a clinical drug, TZ may be quickly translated into treatments for diseases including stroke and sepsis.
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:02:49 GMT 2023
Edited
by admin
on Fri Dec 15 15:02:49 GMT 2023
Record UNII
D32S14F082
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
TERAZOSIN HYDROCHLORIDE
ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN  
Official Name English
TERAZOSIN HYDROCHLORIDE DIHYDRATE [EP MONOGRAPH]
Common Name English
TERAZOSIN HCL 2H20
Common Name English
URODIE
Brand Name English
ITRIN
Brand Name English
TERAZOSIN HYDROCHLORIDE HYDRATE
JAN  
Common Name English
TERAZOSIN HYDROCHLORIDE [USP-RS]
Common Name English
HYTRACIN
Brand Name English
TERAZOSIN HYDROCHLORIDE HYDRATE [JAN]
Common Name English
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(tetrahydro-2-furoyl)piperazine monohydrochloride dihydrate
Systematic Name English
Terazosin hydrochloride [WHO-DD]
Common Name English
HEITRIN
Brand Name English
PIPERAZINE, 1-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-4-((TETRAHYDRO-2-FURANYL)CARBONYL)-, MONOHYDROCHLORIDE, DIHYDRATE
Common Name English
TERAZOSIN (AS HYDROCHLORIDE)
Common Name English
TERAZOSIN MONOHYDROCHLORIDE DIHYDRATE
Common Name English
TERAZOSIN HYDROCHLORIDE [USAN]
Common Name English
TERAZOSIN HYDROCHLORIDE DIHYDRATE
EP   MI  
Common Name English
TERAZOSIN HYDROCHLORIDE [VANDF]
Common Name English
METHANONE, (4-(4-AMINO-6,7-DIMETHOXY-2-QUINAZOLINYL)-1-PIPERAZINYL)(TETRAHYDRO-2-FURANYL)-, HYDROCHLORIDE, HYDRATE (1:1:2)
Systematic Name English
HYTRIN
Brand Name English
ABBOTT-45975
Code English
TERAZOSIN HYDROCHLORIDE DIHYDRATE [MI]
Common Name English
TERAZOSIN HYDROCHLORIDE [USP MONOGRAPH]
Common Name English
TERAZOSIN HYDROCHLORIDE DIHYDRATE [EP IMPURITY]
Common Name English
TERAZOSIN HYDROCHLORIDE [ORANGE BOOK]
Common Name English
NSC-759168
Code English
Classification Tree Code System Code
NCI_THESAURUS C29713
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
Code System Code Type Description
RS_ITEM_NUM
1643452
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY
EVMPD
SUB22323
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY
NCI_THESAURUS
C29491
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY
MERCK INDEX
m10567
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY Merck Index
CAS
70024-40-7
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY
DRUG BANK
DBSALT000326
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY
FDA UNII
D32S14F082
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY
CHEBI
9446
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY
PUBCHEM
63016
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY
DAILYMED
D32S14F082
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY
SMS_ID
100000086021
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY
RXCUI
235224
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY RxNorm
EVMPD
SUB04722MIG
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY
NSC
759168
Created by admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
PRIMARY
Related Record Type Details
SALT/SOLVATE -> SALT/SOLVATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
ANHYDROUS->SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
UNSPECIFIED
EP
Related Record Type Details
ACTIVE MOIETY